Guest guest Posted December 26, 2010 Report Posted December 26, 2010 This is a stunner. In concept, tho, it appears actually antithetical to any mind-body phenom., as a normal placebo, or more powerfully, nocebo, so aptly demonstrates. I must strongly disagree with the conclusion of futuire medical utilization. More realistically, it'll be cold day in hell before an open placebo is used by mainstrem medicine. Nonetheless, a stunner of a result for this study. Dr Einhorn Stamford Miami _____ From: Supertraining [mailto:Supertraining ] On Behalf Of carruthersjam Sent: Saturday, December 25, 2010 12:28 PM Supertraining Subject: Placebos without Deception The below may be of interest: Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015591 Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47¡À18 with IBS diagnosed by Rome III criteria and with a score ¡Ý150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as ¡°placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes¡± or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). Open-label placebo produced significantly higher mean (¡ÀSD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2¡À1.0 vs. 4.0¡À1.1, p<.001) and at 21-day endpoint (5.0¡À1.5 vs. 3.9¡À1.3, p & #8202;= & #8202;.002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p & #8202;= & #8202;.008 and p & #8202;= & #8202;.03) and adequate relief (IBS-AR, p & #8202;= & #8202;.02 and p & #8202;= & #8202;.03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p & #8202;= & #8202;.08). Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent. ============= Carruthers Wakefield, UK Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.